ISCHEMIX
Ischemix, Inc., a pharmaceutical company, develops small molecule drugs for the treatment and prevention of ischemia-reperfusion injury. Its product includes CMX-2043, a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule, as well as is used for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention procedures. The company’s drugs also protect against the damaging effects associated with ischemia in brain and other organs. Ischemix, Inc. was formerly known as CereMedix, Inc. and changed its name to Ischemix, Inc. in February 2006. The company was founded in 1999 and is headquartered in Maynard, Massachusetts.
ISCHEMIX
Industry:
Clinical Trials Medical
Founded:
1999-01-01
Address:
Maynard, Massachusetts, United States
Country:
United States
Website Url:
http://www.ischemix.com
Total Employee:
1+
Status:
Active
Contact:
508 839 2999
Total Funding:
6.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apache Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS Google Maps API
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
ConvaTec
ConvaTec specializes in the development, manufacture, distribution of single-use devices to hospitals and healthcare sectors.
myTomorrows
myTomorrows is a global platform that connects patients with unmet medical needs to treatments in development around the world.
PanTheryx
PanTheryx is a nutrition and biotechnology company that utilizes the cellular and biomolecular processes of bovine colostrum.
Pepgen
PepGen is empowering nucleic acid therapeutics to go the distance.
Current Employees Featured
Founder
Official Site Inspections
http://www.ischemix.com Semrush global rank: 5.92 M Semrush visits lastest month: 1.39 K
- Host name: ecbiz182.inmotionhosting.com
- IP address: 198.46.81.195
- Location: El Segundo United States
- Latitude: 33.9214
- Longitude: -118.413
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90245
More informations about "Ischemix"
Ischemix - Crunchbase Company Profile & Funding
Ischemix, Inc., a pharmaceutical company, develops small molecule drugs for the treatment and prevention of ischemia-reperfusion injury. Its product includes CMX-2043, a cardio-protective …See details»
About - Ischemix
About Ischemix. Ischemix is a privately-held pharmaceutical company that is developing novel cytoprotective compounds for serious diseases and conditions. Accomplishments. Proof of …See details»
Ischemix Company Profile 2024: Valuation, Funding & Investors
Ischemix General Information Description. Developer of therapeutic compounds intended for the treatment of serious diseases and conditions. The company's primary focus of the company is …See details»
Ischemix - Products, Competitors, Financials, Employees, …
About Ischemix. Ischemix is a pharmaceutical company focused on developing cytoprotective therapies for the treatment of serious diseases. The company's main product is a proprietary …See details»
Ischemix - Overview, News & Similar companies | ZoomInfo.com
Aug 25, 2023 Ischemix contact info: Phone number: (508) 839-2999 Website: www.ischemix.com What does Ischemix do? Ischemix is a privately-held drug development …See details»
Ischemix - LinkedIn
Ischemix is a privately-held pharmaceutical company that has developed novel cytoprotective compounds for the prevention and treatment of serious conditions of the kidney, heart and …See details»
Ischemix Company Profile - Office Locations, Competitors ... - Craft
Ischemix is a pharmaceutical company developing cytoprotective compounds for serious neurological diseases and conditions. Its lead compound, CMX-2043, is in preclinical …See details»
Ischemix - Company Profile - Tracxn
Nov 5, 2024 Ischemix - Developer of cytoprotective therapy for traumatic brain injury. Raised a total funding of $6.6M over 2 rounds from 1 investor. Ischemix has 44 competitors.See details»
Ischemix: Contact Details and Business Profile - RocketReach
The NAICS codes for Ischemix are [325, 32, 3254, 32541]. What is the SIC code for Ischemix? The SIC codes for Ischemix are [283, 28]. Top Ischemix Employees David DeWahl President …See details»
Ischemix, Inc. | Maynard, MA, USA Startup - gust.com
Mr. DeWahl joined Ischemix in January 2013 as President and Chief Executive Officer. He was previously Vice President of Corporate Development for Helix Therapeutics, Inc. Mr. DeWahl …See details»
Ischemix CEO and Key Executive Team | Craft.co
Ischemix's Chairman and Chief Scientific Officer is Reinier Beeuwkes. Other executives include David A. Dewahl, President, Chief Executive Officer; Geoffrey E. Clark, Medical Officer and 2 …See details»
Ischemix - Contacts, Employees, Board Members, Advisors & Alumni
Ischemix has 1 current employee profile, Co-founder and Consultant Howard Schneider. Howard Schneider Co-founder and Consultant Unlock even more features with Crunchbase ProSee details»
Ischemix Company Profile | Management and Employees List
Find contact information for Ischemix. Learn about their Manufacturing market share, competitors, and Ischemix's email format.See details»
Ischemix - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jun 5, 2014: Venture Round - …See details»
News - Ischemix
Altasciences Company, Inc. a contract research organization offering a broad array of drug development services, performed the Phase 1 trial at its Montreal, Quebec, Canada facility. ...See details»
Ischemix, Inc. Receives US Department of Defense Funding of $2.9 ...
GRAFTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Ischemix, Inc., a private company focused on developing therapeutics for serious medical conditions, today announced that the …See details»
Ischemix, Inc. Completes Successful Phase 1 Trial of Novel …
Aug 25, 2023 Ischemix, Inc.,a privately-held company focused on developing cytoprotective therapeutics for serious medical conditions, today announced that it has completed an 80 …See details»
Ischemix, Inc. Completes Successful Phase 1 Trial of Novel …
Aug 25, 2023 Ischemix is a privately-held drug development company based in Grafton, MA. The primary focus of the Company is the development of its lead compound, CMX-2043, for …See details»
Altasciences Completes Successful Phase I Trial of Ischemix Novel ...
Aug 30, 2023 Laval, Québec,– Altasciences is pleased to have completed a Phase I trial on Ischemix, Inc.’s novel, proprietary cytoprotective drug candidate, CMX-2043, for the treatment …See details»